Actively Recruiting
Study of How Heparin Treatments Affect Argatroban Measurement in Adults With Blood Clotting Disorders
Led by University Hospital, Strasbourg, France · Updated on 2025-12-24
70
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are investigating how heparins, including unfractionated heparin UFH and low molecular weight heparins LMWH, may interfere with measuring the anticoagulant activity of argatroban, a drug given after heparin therapy for suspected heparin-induced thrombocytopenia. This study focuses on understanding whether heparins affect the accuracy of a modified thrombin time test used to monitor argatrobans anti-IIa activity, an important factor since both clotting and bleeding risks exist in this context. This observational study involves patients anticoagulated with UFH or LMWH whose blood samples are analyzed at the Hematology Laboratory of Strasbourg University Hospitals. The study does not involve new treatments but monitors routine measurements of anti-Xa and anti-IIa activity to see if heparins impact the test results for argatroban. Participants provide blood samples during routine care, which are tested for anti-Xa activity and the anti-IIa activity of argatroban. Researchers will analyze the correlation between measurements to assess interference. The main outcome is measured one hour after analysis using statistical correlation tests. The study aims to improve how anticoagulation is monitored in patients with thromboembolic disease. Participation duration and follow-up details are not specified.
CONDITIONS
Brief Title
HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT
Research Team
A
Agathe HERB, PharmD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
